福元医药：“左甲状腺素钠片”取得注册证

Company Summary - Fuyuan Pharmaceutical received the drug registration certificate for Levothyroxine Sodium Tablets from the National Medical Products Administration, allowing the production of this medication [1] - For the fiscal year 2024, Fuyuan Pharmaceutical's revenue composition is as follows: 93.12% from pharmaceutical preparations, 6.46% from medical devices, 0.36% from other businesses, and 0.06% from other sources [1] - The current market capitalization of Fuyuan Pharmaceutical is 12.4 billion yuan [1] Industry Summary - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]